A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization

被引:12
|
作者
Marsango, Sara [1 ]
Caltabiano, Gianluigi [2 ]
Jimemez-Roses, Mireia [2 ]
Millan, Mark J. [3 ]
Pediani, John D. [1 ]
Ward, Richard J. [1 ]
Milligan, Graeme [1 ]
机构
[1] Univ Glasgow, Coll Med Vet & Life Sci, Inst Mol Cell & Syst Biol, Ctr Translat Pharmacol, Glasgow G12 8QQ, Lanark, Scotland
[2] Univ Autonoma Barcelona, Fac Med, Unitat Bioestadist, Lab Med Computac, Bellaterra 08193, Spain
[3] Ctr Innovat Neuropsychiat, Inst Rech Servier, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
基金
英国医学研究理事会;
关键词
PROTEIN-COUPLED RECEPTORS; M-1 MUSCARINIC RECEPTOR; D3; RECEPTOR; OLIGOMERIC ORGANIZATION; DIMERIZATION; INTERFACE; SEROTONIN; HETERODIMERIZATION; TRANSACTIVATION; SCHIZOPHRENIA;
D O I
10.1038/s41598-017-02249-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The dopamine D-3 receptor (D3R) is a molecular target for both first-generation and several recently-developed antipsychotic agents. Following stable expression of this mEGFP-tagged receptor, Spatial Intensity Distribution Analysis indicated that a substantial proportion of the receptor was present within dimeric/oligomeric complexes and that increased expression levels of the receptor favored a greater dimer to monomer ratio. Addition of the antipsychotics, spiperone or haloperidol, resulted in re-organization of D3R quaternary structure to promote monomerization. This action was dependent on ligand concentration and reversed upon drug washout. By contrast, a number of other antagonists with high affinity at the D3R, did not alter the dimer/monomer ratio. Molecular dynamics simulations following docking of each of the ligands into a model of the D3R derived from the available atomic level structure, and comparisons to the receptor in the absence of ligand, were undertaken. They showed that, in contrast to the other antagonists, spiperone and haloperidol respectively increased the atomic distance between reference a carbon atoms of transmembrane domains IV and V and I and II, both of which provide key interfaces for D3R dimerization. These results offer a molecular explanation for the distinctive ability of spiperone and haloperidol to disrupt D3R dimerization.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization
    Sara Marsango
    Gianluigi Caltabiano
    Mireia Jiménez-Rosés
    Mark J. Millan
    John D. Pediani
    Richard J. Ward
    Graeme Milligan
    [J]. Scientific Reports, 7
  • [2] Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist
    Chien, Ellen Y. T.
    Liu, Wei
    Zhao, Qiang
    Katritch, Vsevolod
    Han, Gye Won
    Hanson, Michael A.
    Shi, Lei
    Newman, Amy Hauck
    Javitch, Jonathan A.
    Cherezov, Vadim
    Stevens, Raymond C.
    [J]. SCIENCE, 2010, 330 (6007) : 1091 - 1095
  • [3] Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D3 dopamine receptor over D2 dopamine receptor
    Appiah-Kubi, Patrick
    Olotu, Fisayo Andrew
    Soliman, Mahmoud E. S.
    [J]. JOURNAL OF MOLECULAR RECOGNITION, 2021, 34 (05)
  • [4] Dopamine D3 receptor ligands with antagonist properties
    Hackling, AE
    Stark, H
    [J]. CHEMBIOCHEM, 2002, 3 (10) : 946 - 961
  • [5] ASSOCIATION BETWEEN DOPAMINE D3 RECEPTOR GENOTYPE AND RESPONSE TO A DOPAMINE D3 RECEPTOR ANTAGONIST IN SCHIZOPHRENIC SUBJECTS.
    Bhathena, A.
    Wang, Y.
    Kraft, J. B.
    Idler, K. B.
    Abel, S. J.
    Holley-Shanks, R. R.
    Robieson, W. Z.
    Spear, B. B.
    Redden, L.
    Katz, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S76 - S76
  • [6] Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor
    Wood, MD
    Boyfield, I
    Nash, DJ
    Jewitt, FR
    Avenell, KY
    Riley, GJ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 407 (1-2) : 47 - 51
  • [7] Analysis of Human Dopamine D3 Receptor Quaternary Structure
    Marsango, Sara
    Caltabiano, Gianluigi
    Pou, Chantevy
    Varela Liste, Mara Jose
    Milligan, Graeme
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (24) : 15146 - 15162
  • [8] Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110
    Park, WK
    Jeong, D
    Yun, CW
    Lee, S
    Cho, H
    Kim, GD
    Koh, HY
    Pae, AN
    Cho, YS
    Choi, KI
    Jung, JY
    Jung, SH
    Kong, JY
    [J]. PHARMACOLOGICAL RESEARCH, 2003, 48 (06) : 615 - 622
  • [9] Anti parkinsonian actions of the selective dopamine D3 receptor antagonist S33084
    Silverdale, MA
    Millan, MJ
    Newman-Tancredi, A
    Crossman, AR
    Brotchie, JM
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (02): : 215 - 215
  • [10] The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
    Wicke, K
    Garcia-Ladona, J
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 424 (02) : 85 - 90